Arcus Biosciences (RCUS) Competitors $10.53 -0.36 (-3.31%) Closing price 03/3/2025 03:59 PM EasternExtended Trading$10.86 +0.33 (+3.09%) As of 03/3/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RCUS vs. ADMA, RNA, ZLAB, BHVN, ALVO, RXRX, SRRK, IMVT, AKRO, and APLSShould you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include ADMA Biologics (ADMA), Avidity Biosciences (RNA), Zai Lab (ZLAB), Biohaven (BHVN), Alvotech (ALVO), Recursion Pharmaceuticals (RXRX), Scholar Rock (SRRK), Immunovant (IMVT), Akero Therapeutics (AKRO), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry. Arcus Biosciences vs. ADMA Biologics Avidity Biosciences Zai Lab Biohaven Alvotech Recursion Pharmaceuticals Scholar Rock Immunovant Akero Therapeutics Apellis Pharmaceuticals ADMA Biologics (NASDAQ:ADMA) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends. Which has stronger valuation and earnings, ADMA or RCUS? ADMA Biologics has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADMA Biologics$382.81M9.78-$28.24M$0.2856.54Arcus Biosciences$258M4.29-$307M-$3.10-3.40 Do analysts rate ADMA or RCUS? ADMA Biologics presently has a consensus target price of $21.25, indicating a potential upside of 34.24%. Arcus Biosciences has a consensus target price of $30.25, indicating a potential upside of 187.27%. Given Arcus Biosciences' higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than ADMA Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Arcus Biosciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk and volatility, ADMA or RCUS? ADMA Biologics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Does the MarketBeat Community favor ADMA or RCUS? ADMA Biologics received 217 more outperform votes than Arcus Biosciences when rated by MarketBeat users. Likewise, 72.08% of users gave ADMA Biologics an outperform vote while only 65.33% of users gave Arcus Biosciences an outperform vote. CompanyUnderperformOutperformADMA BiologicsOutperform Votes41372.08% Underperform Votes16027.92% Arcus BiosciencesOutperform Votes19665.33% Underperform Votes10434.67% Do institutionals & insiders have more ownership in ADMA or RCUS? 75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 3.7% of ADMA Biologics shares are owned by insiders. Comparatively, 12.3% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor ADMA or RCUS? In the previous week, Arcus Biosciences had 30 more articles in the media than ADMA Biologics. MarketBeat recorded 44 mentions for Arcus Biosciences and 14 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.28 beat Arcus Biosciences' score of 0.55 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 9 Very Positive mention(s) 1 Positive mention(s) 13 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive Is ADMA or RCUS more profitable? ADMA Biologics has a net margin of 17.80% compared to Arcus Biosciences' net margin of -102.66%. ADMA Biologics' return on equity of 53.20% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets ADMA Biologics17.80% 53.20% 26.07% Arcus Biosciences -102.66%-45.59%-22.38% SummaryADMA Biologics beats Arcus Biosciences on 12 of the 18 factors compared between the two stocks. Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCUS vs. The Competition Export to ExcelMetricArcus BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$1.11B$7.21B$5.81B$19.94BDividend YieldN/A2.79%4.75%3.90%P/E Ratio-3.346.1524.9534.16Price / Sales4.29187.68375.5530.29Price / CashN/A65.6738.0517.60Price / Book1.716.447.334.70Net Income-$307M$139.03M$3.18B$1.02B7 Day Performance2.68%-3.50%-2.87%-2.20%1 Month Performance-21.47%-9.22%-6.77%-3.99%1 Year Performance-44.61%-12.95%12.32%8.16% Arcus Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCUSArcus Biosciences2.6702 of 5 stars$10.53-3.3%$30.25+187.3%-44.9%$1.11B$258M-3.34500Earnings ReportADMAADMA Biologics3.0855 of 5 stars$15.52-2.0%$21.25+36.9%+186.8%$3.67B$382.81M55.43530Earnings ReportPositive NewsRNAAvidity Biosciences1.121 of 5 stars$30.53-1.9%$65.80+115.5%+45.3%$3.64B$10.12M-10.60190Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap DownZLABZai Lab2.4705 of 5 stars$32.95-2.5%$55.00+66.9%+50.4%$3.61B$355.75M-11.902,175Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeBHVNBiohaven3.4763 of 5 stars$35.46-3.9%$63.15+78.1%-35.5%$3.59BN/A-3.79239Earnings ReportUpcoming EarningsNews CoveragePositive NewsALVOAlvotech2.2676 of 5 stars$11.87-3.3%$18.00+51.6%-29.6%$3.58B$93.38M-6.421,026RXRXRecursion Pharmaceuticals2.2939 of 5 stars$9.00-3.0%$8.75-2.8%-48.6%$3.52B$44.58M-5.88400Earnings ReportGap UpSRRKScholar Rock3.5607 of 5 stars$37.16-1.4%$40.43+8.8%+131.1%$3.48B$33.19M-15.81140IMVTImmunovant2.5004 of 5 stars$20.43-3.9%$45.90+124.7%-47.8%$3.47BN/A-7.80120Analyst ForecastAnalyst RevisionAKROAkero Therapeutics4.1623 of 5 stars$49.60-4.3%$75.86+52.9%+63.8%$3.46BN/A-13.2330Earnings ReportAnalyst ForecastShort Interest ↑Gap DownAPLSApellis Pharmaceuticals3.8766 of 5 stars$27.41-0.4%$46.71+70.4%-62.3%$3.41B$715.22M-13.50770Earnings ReportAnalyst ForecastNews Coverage Related Companies and Tools Related Companies ADMA Biologics Competitors Avidity Biosciences Competitors Zai Lab Competitors Biohaven Competitors Alvotech Competitors Recursion Pharmaceuticals Competitors Scholar Rock Competitors Immunovant Competitors Akero Therapeutics Competitors Apellis Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:RCUS) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
